Kestra Medical Technologies Ltd(KMTS) - 2026 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for the third quarter was $24.6 million, representing a 63% increase compared to the prior year period [9][20] - Gross margin improved to 52.6%, up 9 percentage points year-over-year and 200 basis points sequentially, marking the ninth consecutive quarter of sequential gross margin expansion [9][20] - GAAP net loss was $34.2 million, compared to a GAAP net loss of $21.8 million in the prior year period [24] Business Line Data and Key Metrics Changes - The company accepted over 5,400 prescriptions for the ASSURE System, reflecting a 58% year-over-year increase in prescriptions [9][20] - The conversion rate improved to approximately 46%, up from an adjusted conversion rate of 43% in the prior year period [21] Market Data and Key Metrics Changes - The wearable cardioverter defibrillator (WCD) market is estimated to have grown in the low to mid-teens percentage on a dollar basis in calendar year 2025 [10][11] - The company believes the WCD market will expand into a multi-billion-dollar market in the coming years [10] Company Strategy and Development Direction - The company aims to achieve gross margins of 70% or more over the next few years, supported by strong revenue growth and margin expansion [10][20] - A strategic collaboration with Biobeat Technologies was announced to enhance diagnostic insights for patients, integrating their technology into the product portfolio [13][14] - The company is expanding its sales organization to penetrate existing accounts and attract new prescribers, targeting geographies with high volumes of WCD prescriptions [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong performance and the foundation built for durable growth [18][19] - The management highlighted the importance of clinical data from the ACE-PAS study in driving clinician engagement and market expansion [12][48] Other Important Information - The company became an approved Florida managed Medicaid provider, which is expected to enhance market share in Florida [16][60] - The monthly Medicare reimbursement rate for WCDs increased by 2% to $3,589 as of January 1 [17] Q&A Session Summary Question: Thoughts on early 2027 model and $133 million consensus - Management is confident in delivering top-tier med tech growth in 2027 and will provide more details at the next earnings call [29] Question: Acceleration in WCD market growth - Management noted that increased commercial team size and clinical results are driving market growth, with expectations for continued acceleration [31][34] Question: Prescription growth sources - Approximately 70%-75% of prescription growth is attributed to market share shift, with 25% from new prescribers [38] Question: Competitive environment and pricing - Management indicated no pricing headwinds and emphasized ongoing competition without significant obstacles from competitors [42] Question: Florida Medicaid provider status impact - The approval is expected to enhance growth in Florida, although it will take time to see full benefits [60] Question: CapEx spending as a leading indicator - Management indicated that CapEx spending is aligned with the growth strategy, with expectations for continued investment in inventory and service levels [83] Question: Cash burn outlook - Management expects cash burn to remain in the mid-$20 million range for the next year, excluding specific investments [85]